About this Research Topic
Advances in cardiovascular pharmacology have significantly enhanced patient outcomes through a new wave of medications ranging from anticoagulants and antiplatelet agents to lipid-lowering drugs and targeted molecular treatments. This revolution in cardiovascular therapies promises to manage the broad spectrum of cardiovascular ailments more efficiently than ever before. Yet, amidst this progress, heart failure remains a formidable challenge due to its complex etiologies and varied clinical presentations, thus necessitating an intensified focus on overcoming drug resistance, adverse reactions, and persistent disparities in treatment outcomes.
This Research Topic is dedicated to advancing the understanding of pharmacologic interventions specifically geared towards heart failure, aiming to dissect the complex mechanisms of action, assess therapeutic effectiveness, and evaluate safety profiles of new medications. Efforts will focus on enhancing personalized care thereby heightening overall treatment accessibility and effectiveness. Through detailed reviews and novel research contributions, we target setting new paradigms in heart failure treatment that could bridge the gaps evident in current therapeutic approaches.
To provide comprehensive insights into heart failure treatment, our scope is defined by both the opportunities and the inherent challenges present in current pharmacologic strategies. Contributions are expected to cover a broad range of topics including:
- Detailed analysis of novel drug mechanisms and their clinical implications.
- Assessments of current and emerging drug therapies for heart failure.
- Innovative approaches to combat drug resistance and side effects.
- Discussions on the enhancement of treatment personalization and efficacy.
This call encompasses original research, systematic reviews, and opinion pieces that strive to push the frontier of heart failure therapy, with the goal of offering new perspectives and concrete solutions to this pressing medical issue.
This Research Topic is dedicated to advancing the understanding of pharmacologic interventions specifically geared towards heart failure, aiming to dissect the complex mechanisms of action, assess therapeutic effectiveness, and evaluate safety profiles of new medications. Efforts will focus on enhancing personalized care thereby heightening overall treatment accessibility and effectiveness. Through detailed reviews and novel research contributions, we target setting new paradigms in heart failure treatment that could bridge the gaps evident in current therapeutic approaches.
To provide comprehensive insights into heart failure treatment, our scope is defined by both the opportunities and the inherent challenges present in current pharmacologic strategies. Contributions are expected to cover a broad range of topics including:
- Detailed analysis of novel drug mechanisms and their clinical implications.
- Assessments of current and emerging drug therapies for heart failure.
- Innovative approaches to combat drug resistance and side effects.
- Discussions on the enhancement of treatment personalization and efficacy.
This call encompasses original research, systematic reviews, and opinion pieces that strive to push the frontier of heart failure therapy, with the goal of offering new perspectives and concrete solutions to this pressing medical issue.
Keywords: Cardiac Resynchronization Therapy (CRT), Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Vericiguat
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
